SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage...
– Phase 1 dose-escalation study to evaluate KO-2806 as a monotherapy and in combination with targeted therapies...
– Meaningful antitumor activity observed in recurrent/metastatic HRAS mutant HNSCC, including CR – – Data...
– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies...
– Oral presentation at RAS Summit supports development of next-generation FTI in combination with KRASG12C...
SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage...
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage...
– Enrollment in registration-directed trial of ziftomenib in NPM1-mutant AML continues to outperform...
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage...
FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.